CMG Pharmaceutical Co., Ltd. (058820.KQ)
KRW 2625.0
(-0.57%)
KRW 2625.0
(-0.57%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 15.87 Billion KRW | -6.01% |
| 2022 | 16.89 Billion KRW | 51357.52% |
| 2021 | 32.82 Million KRW | 24.13% |
| 2020 | 26.44 Million KRW | -99.66% |
| 2019 | 7.83 Billion KRW | 1.71% |
| 2018 | 7.7 Billion KRW | 3.93% |
| 2017 | 7.4 Billion KRW | 39.85% |
| 2016 | 5.29 Billion KRW | 14.27% |
| 2015 | 4.63 Billion KRW | 3.0% |
| 2014 | 4.5 Billion KRW | 2.88% |
| 2013 | 4.37 Billion KRW | 39328.88% |
| 2012 | 11.09 Million KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 15.04 Billion KRW | 30.47% |
| 2024 Q1 | 15.9 Billion KRW | 0.19% |
| 2023 Q3 | 14.92 Billion KRW | -11.83% |
| 2023 Q4 | 15.87 Billion KRW | 6.34% |
| 2023 FY | 20.56 Billion KRW | -3.29% |
| 2023 Q1 | 17.1 Billion KRW | 1.25% |
| 2023 Q2 | 16.93 Billion KRW | -0.99% |
| 2022 Q3 | 33.75 Million KRW | 14.58% |
| 2022 Q2 | 29.45 Million KRW | -1.33% |
| 2022 Q1 | 29.85 Million KRW | -9.06% |
| 2022 Q4 | 16.89 Billion KRW | 49945.76% |
| 2022 FY | 21.27 Billion USD | 61.19% |
| 2021 Q3 | 28.45 Million KRW | 13.08% |
| 2021 FY | 13.19 Billion USD | -12.3% |
| 2021 Q2 | 25.15 Million KRW | 3.52% |
| 2021 Q4 | 32.82 Million KRW | 15.38% |
| 2021 Q1 | 24.3 Million KRW | -8.1% |
| 2020 Q4 | 26.44 Million KRW | 3.85% |
| 2020 FY | 15.04 Billion USD | 92.11% |
| 2020 Q1 | 9.19 Billion KRW | 17.39% |
| 2020 Q2 | 24.17 Million KRW | -99.74% |
| 2020 Q3 | 25.46 Million KRW | 5.32% |
| 2019 Q2 | 8.21 Billion KRW | 7.17% |
| 2019 Q1 | 7.66 Billion KRW | -0.44% |
| 2019 Q4 | 7.83 Billion KRW | -6.02% |
| 2019 FY | 26.09 Million USD | 36237.14% |
| 2019 Q3 | 8.33 Billion KRW | 1.44% |
| 2018 Q3 | 8.16 Billion KRW | 5.69% |
| 2018 FY | 21.55 Million USD | 8.53% |
| 2018 Q4 | 7.7 Billion KRW | -5.65% |
| 2018 Q2 | 7.72 Billion KRW | -3.83% |
| 2018 Q1 | 8.03 Billion KRW | 8.39% |
| 2017 Q4 | 7.4 Billion KRW | 17.47% |
| 2017 FY | 19.86 Million USD | 32.23% |
| 2017 Q1 | 6.57 Billion KRW | 24.17% |
| 2017 Q2 | 6.8 Billion KRW | 3.42% |
| 2017 Q3 | 6.3 Billion KRW | -7.29% |
| 2016 Q4 | 5.29 Billion KRW | -13.02% |
| 2016 Q2 | 5.79 Billion KRW | 0.75% |
| 2016 Q1 | 5.75 Billion KRW | 24.03% |
| 2016 Q3 | 6.09 Billion KRW | 5.14% |
| 2016 FY | 15.01 Million USD | -0.16% |
| 2015 Q1 | 5 Billion KRW | 11.23% |
| 2015 Q4 | 4.63 Billion KRW | 9.04% |
| 2015 FY | 15.04 Million USD | -1.88% |
| 2015 Q3 | 4.25 Billion KRW | 7.1% |
| 2015 Q2 | 3.97 Billion KRW | -20.7% |
| 2014 Q3 | 4.53 Billion KRW | -7.0% |
| 2014 Q1 | 4.12 Billion KRW | -5.61% |
| 2014 FY | 15.33 Million USD | 17.54% |
| 2014 Q4 | 4.5 Billion KRW | -0.83% |
| 2014 Q2 | 4.88 Billion KRW | 18.19% |
| 2013 FY | 13.04 Million USD | 17.56% |
| 2013 Q1 | 3.16 Billion KRW | 28383.99% |
| 2013 Q2 | 3.28 Billion KRW | 4.03% |
| 2013 Q3 | 4.5 Billion KRW | 37.11% |
| 2013 Q4 | 4.37 Billion KRW | -2.96% |
| 2012 Q4 | 11.09 Million KRW | 0.0% |
| 2012 FY | 11.09 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 20.85 Billion KRW | 23.887% |
| Celltrion Pharm, Inc. | 100.42 Billion KRW | 84.191% |
| Huons Global Co., Ltd. | 121.81 Billion KRW | 86.968% |
| DongKook Pharmaceutical Co., Ltd. | 138.34 Billion KRW | 88.524% |
| Enzychem Lifesciences Corporation | 14.94 Billion KRW | -6.222% |
| Humedix Co., Ltd. | 28.62 Billion KRW | 44.539% |
| Boditech Med Inc. | 31.6 Billion KRW | 49.765% |
| EuBiologics Co., Ltd. | 13.34 Billion KRW | -18.995% |
| FutureChem Co.,Ltd | 1.37 Billion KRW | -1055.018% |
| Huons Co., Ltd. | 76.59 Billion KRW | 79.274% |
| BNC Korea Co., Ltd. | 11.39 Billion KRW | -39.341% |
| AptaBio Therapeutics Inc. | - KRW | -Infinity% |